SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Sea Ltd. is an internet and mobile platform company, which engages in the provision of online gaming services. It operates through the following segments: Digital Entertainment, E-Commerce, and Digital Financial Services. The Digital Entertainment segment offers and develops mobile and PC online games. The E-Commerce segment manages a third-party marketplace through the Shopee mobile app and websites that connect buyers and sellers. The Digital Financial Services segment includes a variety of payment services and loans to individuals and businesses through SeaMoney. Sea was founded by Xiao Dong Li, Gang Ye, and Jing Ye Chen on May 8, 2009 and is headquartered in Singapore.

Sea Ltd - ADR

Sea Ltd. is facing significant selling pressure as investors grapple with margin compression, intense regional competition, and ongoing frustration over management's capital allocation strategy. While some long-term investors highlight strong revenue growth and a massive addressable market, current sentiment is dominated by technical breakdowns and concerns that heavy investment in logistics could weigh on near-term profitability.

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

CRISPR Therapeutics is trending as investors digest a recent $550 million convertible note offering, which some view as a strategic move to extend runway for clinical pipeline development despite immediate share price pressure. The community remains deeply divided between long-term bulls betting on a potential buyout or major trial catalysts later this year, and frustrated traders venting over persistent management-related sell-offs and the stock's struggle to sustain price momentum.

MercadoLibre, Inc. engages in the development of an online commerce platform with a focus on e-commerce and related services. It operates through the following geographical segments: Brazil, Argentina, Mexico, and Other Countries. The Other Countries segment refers to Chile, Colombia, Costa Rica, Dominican Republic, Ecuador, Panama, Peru, Bolivia, Honduras, Nicaragua, El Salvador, Guatemala, Paraguay, Uruguay, and the United States of America. Its products provide a mechanism for buying, selling, and paying as well as collecting, generating leads, and comparing lists through e-commerce transactions. The company was founded by Marcos Eduardo Galperin on October 15, 1999 and is headquartered in Montevideo, Uruguay.

MercadoLibre Inc

MercadoLibre is trending as investors debate the impact of high-conviction insider buying from executives and speculative interest regarding potential regional growth catalysts. Market participants remain focused on the company's long-term ecosystem dominance in Latin America versus near-term margin pressures stemming from aggressive reinvestment in logistics and fintech.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group is experiencing intense market volatility and a sharp sell-off following a series of major corporate announcements, including the appointment of a new CEO and a significant capital raise through a follow-on offering. Investors are expressing deep frustration over ongoing share dilution, while the community remains sharply divided between those viewing the current valuation as a distressed 'generational buying opportunity' and those warning of imminent bankruptcy and further reverse splits.

NuScale Power Corp. provides proprietary and innovative advanced small modular reactor (SMR) nuclear technology, with a mission to help power the global energy transition by delivering safe, scalable, and reliable carbon-free energy. Its products include VOYGR SMR Plants and Energy Exploration (E2) Centers. The company was founded by José N. Reyes in 2007 and is headquartered in Corvallis, OR.

NuScale Power Corporation - Ordinary Shares - Class A

NuScale Power Corp

NuScale Power is attracting intense community attention as part of a broader nuclear energy revival, fueled by growing demand for 24/7 power from AI data centers and new federal initiatives for space-based nuclear reactors. While some investors are accumulating shares on weakness and eyeing a long-term recovery, others are deeply concerned by the stock's significant decline, persistent short interest, and ongoing corporate divestment, leading to heated debates over whether this is a structural buying opportunity or a speculative value trap.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is seeing active community debate as investors weigh long-term utility goals against frustration over stagnant price action and the emergence of Janction. While some traders are focused on technical resistance levels and accumulation strategies, others are vocal about their skepticism regarding the project's roadmap and leadership communication.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is experiencing heightened investor interest driven by anticipation for upcoming clinical data presentations and a potential BLA submission later this year. The community is actively discussing the stock's high short interest and limited effective float, fueling speculation about a possible short squeeze and long-term valuation potential relative to sector peers.

RaveDAO is a global community uniting music, technology, and purpose. Since their first sold-out event at Dubai 2024, they have expanded across Europe, the Middle East, North America, and Asia, hosting world-class experiences with over 100,000 total attendees and 3,000+ attendees for each event.  RaveDAO has worked with top-tier artists like Vintage Culture, Don Diablo, Chris Avantgarde, Lilly Palmer, MORTEN, Bassjackers, and GENESI and has support from Binance, OKX, Bitget, and Polygon. RaveDAO is redefining live entertainment in Web3 and has active partnerships with 1001Tracklists, AMF, and Warner Music.  Beyond the dance floor, RaveDAO channels energy and attention toward impact. In 2025 alone, proceeds from its events helped restore sight to 400+ cataract patients in Nepal and fund over 150 meditation programs across the U.S.

RaveDAO

RaveDAO is experiencing extreme volatility following a massive surge and subsequent sharp decline, with community members fiercely debating whether the token is a legitimate project or a textbook pump-and-dump scheme. The project has publicly denied involvement in the price manipulation, while on-chain data and analyst warnings regarding highly concentrated token ownership continue to fuel intense speculation and caution among investors.

Cava Group, Inc. is a holding company, which engages in the category-defining Mediterranean fast-casual restaurant brand, bringing together healthful food and bold, satisfying flavors at scale. It operates through the following segments: CAVA and CAVA Foods. The CAVA segment includes the operations of all company-owned CAVA restaurants. The CAVA Foods segment includes the production of dips and spreads used in CAVA restaurants as well as sales from the consumer-packaged goods (CPG) business. The company was founded by Brett Schulman, Ike Grigoropoulus, Dimitri Moshovitis, and Theodore Xenohristos in 2010 and is headquartered in Washington, DC.

Cava Group Inc

CAVA Group Inc

CAVA is trending following a strong quarterly earnings report that topped revenue and profit expectations, signaling robust growth in same-store sales and aggressive store expansion. Investors are actively debating the company's premium valuation compared to industry peers like Chipotle, with community sentiment split between enthusiasm for its rapid unit growth and skepticism regarding its long-term margin sustainability.

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

AMGEN Inc.

Amgen is currently generating significant market chatter driven by a surge in demand for its cardiovascular drug Repatha, which recently reported impressive clinical trial results. Investors are also closely monitoring the company's progress on its obesity treatment pipeline, MariTide, as Amgen seeks to position itself as a formidable competitor in the rapidly evolving metabolic market.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Esperion Therapeutics (NASDAQ:ESPR) Sees Large Volume Increase - Here's What Happened

Esperion Therapeutics (NASDAQ:ESPR) Sees Strong Trading Volume - What's Next...

Esperion Therapeutics Target of Unusually Large Options Trading (NASDAQ:ESPR)

Esperion Therapeutics, Inc. (NASDAQ:ESPR - Get Free Report) was the target of unusually large options trading activity on Wednesday. Stock investors purchased 5,077 call options on the stock. This is...

Esperion Therapeutics (NASDAQ:ESPR) Trading Down 5.2%  - Here's What Happened

Esperion Therapeutics (NASDAQ:ESPR) Stock Price Down 5.2% - What's Next...

Esperion Therapeutics Highlights 38% Revenue Growth, Enbumyst Launch Plan at Needham Conference

Esperion Therapeutics (NASDAQ:ESPR) outlined its commercial progress and strategic priorities at Needham & Company's 25th Annual Healthcare Conference, highlighting revenue growth, new clinical and guideline tailwinds for its cholesterol franchise, and the recent acquisition of Corstasis Therape...

Esperion Therapeutics (ESPR) Down 10% Since Last Earnings Report: Can It Rebound?

Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Esperion Therapeutics (NASDAQ:ESPR) Shares Down 8.6% - Here's Why

Esperion Therapeutics (NASDAQ:ESPR) Shares Down 8.6% - Should You Sell...

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Average Rating of "Moderate Buy" from Analysts

Esperion Therapeutics, Inc. (NASDAQ:ESPR - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the eight ratings firms that are covering the stock, MarketBeat reports. One...

Esperion Therapeutics, Inc. $ESPR Shares Purchased by JPMorgan Chase & Co.

JPMorgan Chase & Co. raised its stake in Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) by 68.4% in the third quarter, according to the company in its most recent disclosure with the...

Zacks Research Has Negative Forecast for ESPR Q2 Earnings

Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - Research analysts at Zacks Research reduced their Q2 2026 EPS estimates for shares of Esperion Therapeutics in a report issued on Tuesday...

Q4 EPS Estimate for Esperion Therapeutics Raised by Analyst

Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - Equities researchers at Zacks Research upped their Q4 2026 earnings per share (EPS) estimates for shares of Esperion Therapeutics in a...

Esperion Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of oral therapies for elevated low-density lipoprotein cholesterol. The firm offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	-$0.02	--	--	N/A
Q4 '25	$0.24	$0.22	-9.59%	MISSED
Q3 '25	-$0.08	-$0.16	-104.27%	MISSED
Q2 '25	-$0.15	-$0.02	86.27%	BEAT
Q1 '25	-$0.15	-$0.21	-35.69%	MISSED

ESPR
Esperion Therapeutics Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q1 '26

Historical Earnings

Latest ESPR News

ESPREsperion Therapeutics Inc.